Telix Pharmaceuticals (TLX) last issued guidance on October 20, 2026 for fiscal year 2026. The company guided revenue in the range of for the period.

Compared to prior guidance, Telix Pharmaceuticals maintained its revenue forecast from a prior range of $247M - $247M.

Telix Pharmaceuticals has issued 11 guidance updates between February 20, 2025 and October 20, 2026. During this period, the company raised its outlook 3 times and lowered it 4 times, providing investors with insight into management's evolving expectations.